FDA Grants Approval for Mylan's Liraglutide ANDA213155
The FDA has granted approval for Mylan's Abbreviated New Drug Application (ANDA) for Liraglutide.
Published: June 23, 2026
Updated: June 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Endocrinology / GLP-1 Agonist
Company: Mylan
Asset: Liraglutide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mylan
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Mylan's liraglutide ANDA213155 introduces a new competitor in the GLP-1 agonist market, which could disrupt pricing and market dynamics. Established players like Novo Nordisk may need to reassess their strategies to maintain market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Mylan's launch timeline and market uptake of their liraglutide product.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.